CSL has received advice from Baker McKenzie regarding its strategic partnership with privately held Dutch biotech company VarmX BV to support the development of VMX-C001 and the signing of a contract with VarmX shareholders that gives CSL the sole right to purchase all issued and outstanding shares of the business.